stockrowHaemonetics Corporation (HAE) vs 10x Genomics (TXG)
- Haemonetics Corporation HAE 119.96 −3.34%
- 10x Genomics TXG 57.62 −0.76%
Haemonetics Corporation and 10x Genomics are both Medical Devices companies. 10x Genomics is the larger, with a market value of $7.6B against $5.7B — 1.3× the size. 10x Genomics has negative trailing earnings, so its P/E is not meaningful; Haemonetics Corporation trades at 54.5×. Haemonetics Corporation grew revenue faster over the last twelve months: 4.11% against −4.28%. Haemonetics Corporation has the higher net margin (7.52% vs −12.2%) and the higher return on invested capital (6.31% vs −20.2%). Across the 20 metrics below, Haemonetics Corporation leads on 15 and 10x Genomics on 5.
Valuation
Profitability
| Metric | HAE | TXG | Medical Devices median |
|---|---|---|---|
| Gross margin | 59.63% | 70.03% | 57.76% |
| Operating margin | 12.80% | (14.33%) | (15.07%) |
| Net margin | 7.52% | (12.18%) | (14.45%) |
| Free cash flow margin | 24.95% | 19.68% | (3.88%) |
| Return on equity | 11.89% | (9.40%) | (10.35%) |
| Return on assets | 4.28% | (7.47%) | (17.26%) |
| Return on invested capital | 6.31% | (20.20%) | (5.27%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack